Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Evolving Treatment Strategies for the Management of Type 2 Diabetes

(2011) William T. Cefalu   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Proportion of patients at HbA1c target

(2011) K. Esposito et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

(2011) David R. Whiting et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Overview of Newer Agents: Where Treatment Is Going

(2010) Ralph A. DeFronzo   AMERICAN JOURNAL OF MEDICINE

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

(2009) Michael F. Pollack et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes in Japan: a review of disease burden and approaches to treatment

(2009) Susan E. Neville et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL